One-stage Breast Reconstruction Using Dermal Matrix/Implant Versus Two-stage Expander/Implant Procedure (AllodermRCT)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Currently the two-stage tissue expander/implant (TE/I) technique is the standard breast reconstructive option for breast cancer patients selected for immediate, skin-sparing mastectomy. This procedure has been demonstrated to be oncologically safe in patients with specific criteria for early stage breast cancer. The primary drawback, however, is that it requires two separate procedures under general anesthesia and multiple office visits for expander inflation to create the breast mound. Acellular dermal matrix has gained widespread acceptance for use in breast reconstruction and other areas and has the potential to provide support to the breast implant without tissue expansion in a one-stage procedure. The purpose of the study is to test this new procedure and to evaluate the impact of one-stage breast reconstruction using acellular dermis compared to the standard two-stage expander/implant technique on measures of patient satisfaction and quality of life.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer |
Procedure: One-stage dermal matrix/implant procedure Procedure: Two-stage tissue expander/implant procedure |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Acellular Dermal Matrix in One-Stage Breast Reconstruction: A RCT |
- BreastQ quality of life and satisfaction questionnaire [ Time Frame: Baseline, 2 weeks, 6 and 12 months post-op ] [ Designated as safety issue: No ]
- Overall Aesthetic Outcome (panel of experts) [ Time Frame: Baseline and 12 months post-op ] [ Designated as safety issue: No ]
- Short and long term surgical complication rates [ Time Frame: Baseline, 2 weeks, 6 and 12 months post-op ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 144 |
| Study Start Date: | August 2009 |
| Estimated Study Completion Date: | September 2014 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: One-stage dermal matrix/implant
One-stage breast reconstruction with dermal matrix and implant
|
Procedure: One-stage dermal matrix/implant procedure
One-stage breast reconstruction with dermal matrix and implant
Other Name: Alloderm
|
|
Active Comparator: Two-stage tissue expander/implant
Two-stage breast reconstruction with tissue expander and implant
|
Procedure: Two-stage tissue expander/implant procedure
Two-stage breast reconstruction with tissue expander and implant
|
Detailed Description:
Recently, there has been significant focus on the performance of skin-sparing mastectomies in certain types of breast cancer patients. These treatments may be performed for prophylactic mastectomy but also have been demonstrated to be oncologically safe in patients with specific criteria for early stage breast cancer. Currently, the two-stage tissue expander/implant (TE/I) technique is the standard breast reconstructive option for breast cancer patients selected for immediate, skin-sparing mastectomy, however there are significant disadvantages as this technique requires two separate surgeries and multiple office visits to complete that may affect a patients quality of life. Medically safe compounds such as acellular dermal matrix have been developed that have the potential to support breast implants without requiring numerous tissue expansions and consequently providing the potential for a one-stage breast implant/reconstruction procedure for immediate, skin-sparing mastectomies.
To examine patient satisfaction, quality of life and overall aesthetic outcome achieved using the acellular dermal matrix facilitated one-staged breast reconstruction at 2 weeks, 6 & 12 months following completion of the reconstruction. Hypothesis 2: Patient satisfaction, quality of life and overall aesthetic outcome achieved using the acellular dermal matrix facilitated one-stage breast reconstruction is superior to that following the standard two-stage tissue expander/ implant breast reconstruction technique in selected mastectomy patients.
To determine the short and long-term operative complication rates associated with the use of dermal matrix in one-stage immediate breast reconstruction following skin-sparing mastectomy. Hypothesis 1: The use of acellular dermal matrix in one-stage immediate prosthetic breast reconstruction is associated with decreased short and long-term postoperative complications compared with the traditional two staged tissue expander/implant procedure.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients who undergo immediate, implant-based reconstruction following skin-sparing and nipple-sparing mastectomy.
- Patients who are older than 18 years of age and who understand English enough to complete the study questionnaires.
Exclusion Criteria:
- Patient refusal, patients with documented psychiatric history of psychosis or mental disorder excluding depression, patients who are active smokers.
- Patients who will undergo any of the following: Autologous tissue reconstruction, patients with prior history of radiation or expected to receive post-operative radiation, patients who are pregnant, patients with grade III ptosis.
- Intraoperative exclusion of those whose mastectomy flaps are deemed to be too thin or have significant ischemia.
Contacts and Locations| Contact: Toni Zhong, MD | 416-340-3858 | toni.zhong@uhn.on.ca |
| Contact: Kate Butler, MHSc | 416-340-4800 ext 2343 | kbutler@uhnres.utoronto.ca |
| Canada, Alberta | |
| Tom Baker Cancer Centre | Recruiting |
| Calgary, Alberta, Canada, T2N 4N2 | |
| Contact: Claire Temple-Oberle, MD, FRCS (C) 403-521-3275 claire.temple-oberle@albertahealthservices.ca | |
| Contact: Carmen Webb, PhD 403-521-3012 carmen.webb@albertahealthservices.ca | |
| Principal Investigator: Claire Temple-Oberle, MD, FRCS (C) | |
| Canada, British Columbia | |
| Vancouver General Hospital | Recruiting |
| Vancouver, British Columbia, Canada, V5Z 1M9 | |
| Contact: Sheina Macadam, MD FRCSC MHS 604-876-1688 drsmacadam@gmail.com | |
| Contact: Joline T. Choi, MSc 604-875-4111 ext 68489 joline.choi@ubc.ca | |
| Principal Investigator: Sheina Macadam, MD FRCSC MHS | |
| Sub-Investigator: Peter A. Lennox, MD FRCSC | |
| Canada, Ontario | |
| Plastic and Reconstructive Surgery, University Health Network | Recruiting |
| Toronto, Ontario, Canada, M5G 2C4 | |
| Contact: Toni Zhong, MD FRCS(C) 416-340-3858 toni.zhong@uhn.on.ca | |
| Contact: Kate Butler, MHSc 416-340-4800 ext 2343 kbutler@uhnres.utoronto.ca | |
| Principal Investigator: Toni Zhong, MD FRCS(C) | |
| Sub-Investigator: Stefan OP Hofer, MD FRCS(C) | |
| Plastic Surgery, Women's College Hospital | Recruiting |
| Toronto, Ontario, Canada, M5G 1N8 | |
| Contact: Mitchell Brown, MD FRCS(C) 416-323-6336 krista@torontoplasticsurgery.com | |
| Contact: Krista Martin 416-323-6336 krista@torontoplasticsurgery.com | |
| Principal Investigator: Mitchell Brown, MD FRCS(C) | |
| Sub-Investigator: John Semple, MD FRCS(C) | |
| Sub-Investigator: Brett Beber, MD FRCS(C) | |
| Principal Investigator: | Toni Zhong, MD FRCS(C) | University Health Network, Toronto |
| Principal Investigator: | Mitchell Brown, MD FRCS(C) | Women's College Hospital |
| Principal Investigator: | Stefan Hofer, MD FRCS(C) | University Health Network, Toronto |
| Principal Investigator: | John Semple, MD FRCS(C) | Women's College Hospital |
| Principal Investigator: | Brett Beber, MD FRCS(C) | Women's College Hospital |
More Information
No publications provided
| Responsible Party: | University Health Network, Toronto |
| ClinicalTrials.gov Identifier: | NCT00956384 History of Changes |
| Other Study ID Numbers: | PSEF-137034 |
| Study First Received: | August 7, 2009 |
| Last Updated: | January 18, 2013 |
| Health Authority: | Canada: Health Canada |
Keywords provided by University Health Network, Toronto:
|
Breast reconstruction Early stage Skin-saving mastectomy |
Prophylactic mastectomy Acellular dermal matrix BRCA Mutation Carriers |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
ClinicalTrials.gov processed this record on May 23, 2013